NYSE:ANRO) Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at ...

Neuroscientific studies have shed light on how rituals affect the brain's response to failure, particularly through the lens ...

Alto Neuroscience has reported positive results from its Phase I clinical trial of the PDE4 inhibitor, ALTO-101, for treating cognitive impairment associated with schizophrenia (CIAS). The study ...

Neuroscience research reveals that integrating emotion and meaning into information can significantly enhance memory and ...

April 23, 2024--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative ...

One such theory that’s gained traction is the triarchic theory of intelligence, developed by psychologist Robert J. Sternberg ...

CNS drug developers should prioritize the discovery of novel biomarkers through objective testing methods that go beyond genetics, says LinusBio CEO Manish Arora, PhD.

The University System of Georgia Board of Regents has approved a new Neuroscience and Neurotechnology Ph.D. Program at ...

Brett Wall is executive vice president and president of neuroscience at Medtronic. Here are five things to know about him: 1. Mr. Wall oversees Medtronic's neuroscience portfolio which has five ...

A big boost is coming to local ALS research in the form of $13.5 million gift to the University of Cincinnati's Gardner ...